United States Ovarian Cancer
Therapeutics Market is expected to grow at an impressive rate during the
forecast period, 2024-2028. The major factors include the increasing incidence
of ovarian cancer, technological advancements in diagnosis and treatment,
increasing awareness among patients and healthcare professionals, aging
population, and increasing healthcare expenditure.
Epithelial ovarian cancer (EOC),
which develops from the ovary's epithelium, is the most prevalent form of
ovarian cancer. One of the most prevalent cancers in women is ovarian cancer.
Despite accounting for more fatalities than the other cancers of the feminine
genital system, it is the fifth most common cancer among women overall. Rare
early detection of this type of cancer makes treatment tough at advanced
stages.
According to the American Cancer
Society's estimations, 13,270 women will die from ovarian cancer in the United
States in 2023 and 19,710 women will acquire a new diagnosis of the cancer.
The rising incidence of ovarian
cancer in the United States is the main factor driving the market for ovarian
cancer therapeutics. The incidence of ovarian cancer, which is the fifth most
frequent malignancy among women in the nation, has been increasing recently.
Ovarian cancer therapies are in high demand because of the rising incidence,
which has been fueling the market's expansion.
Better ovarian cancer diagnosis
and treatment techniques have been created due to technological advancements.
The precision of diagnosis has increased since the development of new imaging
techniques including positron emission tomography (PET) and magnetic resonance
imaging (MRI). Furthermore, the use of targeted therapies for the treatment of
ovarian cancer, such as PARP inhibitors, has shown promising results. With the
development of more potent ovarian cancer therapies as a result of these
technological developments, the market has continued to expand.
A recent study conducted by the
Wilmot Cancer Institute and published in the journal of Obstetrics and
Gynecology has shown that a novel method can successfully predict cancer in
people who have a lesion or cyst in the pelvic area and collect stray ovarian
cancer cells from a simple blood test.
In the United States, numerous
clinical trials are currently underway to explore new therapies and approaches
for the treatment of ovarian cancer. These trials include the use of PARP
inhibitors, immunotherapy, combination therapy, and targeted therapies, among
others. Through these trials, researchers aim to improve patient outcomes and
ultimately find a cure for this challenging disease. The results of these
clinical trials will play a critical role in advancing the understanding of
ovarian cancer and developing more effective treatment options for patients.
Patents related to ovarian
cancer therapeutics in the United States provide exclusive rights to
pharmaceutical companies to manufacture, sell and market their products. These
patents encourage innovation and research and development in the field of ovarian
cancer therapeutics by providing a financial incentive for companies to invest
in developing new drugs and treatments. Additionally, these patents help to
ensure that patients have access to safe and effective medications by requiring
regulatory approval before a drug can be marketed. Patents related to ovarian
cancer therapeutics also allow for the creation of a competitive market, which
can help to drive down costs and improve patient access to treatment.
The prevalence of ovarian cancer
is anticipated to increase as the United States population ages. This is due to
the higher prevalence of ovarian cancer in women over 50. The market will
continue to expand as demand for ovarian cancer therapies rises along with the
aging population.
The cost of healthcare has been
rising in the United States over the past few years. Access to healthcare
services, particularly treatments for ovarian cancer, has expanded as a result
of the rise in healthcare expenditure. Millions of Americans now have easier
access to healthcare due to the Affordable Care Act, including individuals who
have ovarian cancer. The market is expanding as a result of the rising demand
for ovarian cancer therapies brought on by this improved access to healthcare.
Although the market for ovarian
cancer therapeutics in the United States is expected to grow, a number of
challenges are preventing this from occurring. These challenges include
expensive treatment costs, a dearth of effective early diagnostic tools,
treatment resistance, and a lack of patient understanding.
The high cost of therapy is one
of the biggest challenges the US ovarian cancer therapeutics market is now
facing. Being a complicated condition, ovarian cancer usually requires a
combination of surgical removal, chemotherapy, and targeted therapy. Many
people may find it difficult to acquire these treatments due to their high
cost. Insurance coverage might not always pay the whole cost of care, and some
patients may find out-of-pocket costs to be considered a burden.
Resistance to therapy can
develop in ovarian cancer over time, which can reduce the efficacy of therapy.
Genetic mutations and alterations in the tumor microenvironment are just two of
the many processes by which this resistance might arise. Disease progression
and poor patient outcomes might result from resistance to treatment.
In the United States, there have
been significant recent advancements in the treatment of ovarian cancer. The
discovery of novel and efficient treatments for ovarian cancer is being aided
by the approval of PARP inhibitors, the introduction of immunotherapy, the
development of combination therapies, the use of precision medicine, and
collaborative studies.
The development of novel
treatments for ovarian cancer is being sped up by collaborative research initiatives
like the Ovarian Cancer Research Alliance (OCRA). To fund the development of
innovative therapies, these efforts bring together governmental organizations,
nonprofits, and pharmaceutical firms. New ovarian cancer therapies are
anticipated to emerge and be approved more quickly as a result of this
collaborative strategy.
Recent research has shown that
the effectiveness of ovarian cancer treatment can be enhanced by combining
multiple kinds of therapy. For instance, it has been demonstrated that giving
patients with advanced ovarian cancer chemotherapy and PARP inhibitors together
enhances response rates and survival. The potential to improve patient outcomes
of various combination medicines, including immunotherapy and targeted therapy,
is also being investigated.
Prevalence of Ovarian Cancer and
Growing Aging Population
Due to factors such rising
ovarian cancer prevalence and an aging population, the market for ovarian
cancer therapeutics in the United States is growing. The prevalence of
ovarian cancer is predicted to rise further with the aging of the United States
population. Ovarian cancer incidence rises with age.
Pharmaceutical companies have
expanded their research and development efforts as a result, leading to the
creation of novel and improved treatments for ovarian cancer.
Additionally, the development of
targeted therapies that can specifically target cancer cells while sparing
healthy cells has been facilitated by technological advancements and a deeper
understanding of the molecular biology of ovarian cancer. Ovarian cancer
therapeutics market expansion in the United States has been further fueled
by this.
Download Free Sample Report
Need For More Effective Options
for Treatment
Ovarian cancer treatments market
expansion in the United States is largely being driven by the demand for more
potent treatment alternatives. Despite advancements in cancer therapy, ovarian
cancer remains a challenging illness to treat, and there is an increasing need
for novel and better medicines.
The traditional treatment for
ovarian cancer for a long time has been chemotherapy, although it has a low
rate of success and can have serious adverse effects. The fact that many
patients eventually develop resistance to chemotherapy also reduces the range
of available treatments.
Pharmaceutical companies are
making significant investments in research and development to create new
therapies that can enhance patient outcomes in order to address the growing
demand for more effective treatments. As a result, targeted medicines,
immunotherapies, and combination therapies were created; these treatments have
shown promise in clinical studies.
Furthermore, the Food and Drug
Administration (FDA) has recently approved a number of novel medications for
the treatment of ovarian cancer, including angiogenesis inhibitors and PARP
inhibitors. These medications provide patients with ovarian cancer with new
therapy alternatives, which has helped in the expansion of the ovarian cancer
treatments market in the United States.
Market Segmentation
United States Ovarian Cancer
Therapeutics Market can be segmented by treatment, tumor type, distribution
channel, region and competitive landscape. By treatment, the United States
Ovarian Cancer Therapeutics Market can be segmented into Chemotherapy,
Radiation Therapy, Immunotherapy, Hormonal Therapy, and Others. Based on tumor
type, the United States Ovarian Cancer Therapeutics Market is divided into
epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell
tumor, and sex cord-stromal tumor. Based on distribution channel, the market is
divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Market Players
AstraZeneca, Genentech, Inc.,
GlaxoSmithKline PLC, Janssen Biotech, Inc., Merck & Co., Inc., Novartis
International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc. are among some
of the leading companies operating in the market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, and CAGR for 2018-2022
and 2023-2028
|
|
Report coverage
|
Revenue forecast, company share, competitive landscape, growth
factors, and trends
|
|
Segments covered
|
By Drug Class
By Tumor Type
By Distribution Channel
|
|
Regional scope
|
Northeast Region; Midwest Region; South Region; West Region
|
|
Key companies profiled
|
AstraZeneca, Genentech, Inc., GlaxoSmithKline
PLC, Janssen Biotech, Inc., Merck & Co., Inc., Novartis International AG,
Pfizer Inc., Regeneron Pharmaceuticals, Inc.
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United States
Ovarian Cancer Therapeutics Market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:
- United States Ovarian Cancer Therapeutics
Market, By Treatment
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Hormonal Therapy
- Others
- United States Ovarian Cancer Therapeutics
Market, By Tumor Type
- Epithelial Ovarian Cancer
- Ovarian Low Malignant
Potential Tumor
- Germ Cell Tumor
- Sex Cord-Stromal Tumor
- United States Ovarian Cancer Therapeutics
Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Competitive Landscape
Company Profiles: Detailed
analysis of the major companies present in the United States Ovarian Cancer
Therapeutics Market
Available Customizations:
With the given market data,
TechSci Research offers customizations according to a company’s specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
United States Ovarian Cancer Therapeutics
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]